Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis : Episode 4

Opinion

Video

June 21, 2024

Examining Key Unmet Needs in Multiple Sclerosis

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Heidi Crayton, MD

Key opinion leaders discuss the most significant unmet needs in the current treatment landscape for multiple sclerosis.

EP: 1.Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

EP: 2.Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression

EP: 3.Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis

EP: 4.Examining Key Unmet Needs in Multiple Sclerosis

EP: 5.Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies

EP: 6.MS Treatment Guidelines: Expert Insights on Updates and Decision-Making

EP: 7.Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

EP: 8.Examining Challenges with Drug Switching and Step Therapy in MS Treatment

EP: 9.Typical Payer Coverage Criteria for Multiple Sclerosis Therapies

EP: 10.BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment

EP: 11.Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

EP: 12.Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies

EP: 13.Multiple Sclerosis: Looking Toward the Future

What do you view as the biggest unmet needs in the current treatment landscape for MS?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos

Dr Elise Tremblay

4 experts in this video

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions